TABLE 1.
Basic characteristics of included studies.
| Author | Year | Country | Sample size (EG) | Sample size (CG) | PCI | Control intervention | Endpoints | Follow-up time (months) | Modified jadad scale |
|---|---|---|---|---|---|---|---|---|---|
| Cao and Zhao (2020) | 2020 | China | 68 | 68 | No | NR | ①②④⑥ | 2 | 3 |
| Wang et al. (2020) | 2020 | China | 80 | 80 | Yes | Valsartan | ①③⑥ | 6 | 4 |
| Zhao (2020) | 2020 | China | 62 | 61 | Yes | Valsartan | ①③ | 6 | 3 |
| Haiyan and Xianghua (2021) | 2021 | China | 68 | 69 | Yes | Enalapril | ①③⑤⑥ | 6 | 4 |
| Cui (2021) | 2021 | China | 104 | 98 | Yes | Valsartan | ①②③④⑤⑥ | 6 | 4 |
| Dong (2021) | 2021 | China | 64 | 64 | Yes | Enalapril | ①③⑤⑥ | 6 | 4 |
| Jiang (2021) | 2021 | China | 100 | 100 | No | Valsartan | ①②③④⑥ | 2 | 3 |
| Liu and Zhou (2021) | 2021 | China | 60 | 60 | Mixed | Benazepril | ①②③⑥ | 2 | 4 |
| Wang et al. (2022) | 2022 | China | 60 | 60 | No | ACEI | ⑥ | 1 | 4 |
| Fu and Xu (2022) | 2022 | China | 63 | 63 | Yes | Fosinopril sodium | ①②③⑤⑥ | 6 | 4 |
| Sheng (2022) | 2022 | China | 60 | 60 | Yes | Benazepril | ①②③⑤⑥ | 6 | 4 |
| Xie (2022) | 2022 | China | 50 | 50 | No | Valsartan | ①② | NR | 3 |
| Zhou (2022) | 2022 | China | 107 | 110 | Yes | Benazepril | ①②③⑤⑥ | 6 | 5 |
| Jiao et al. (2023) | 2023 | China | 51 | 51 | Yes | Enalapril | ①②③⑥ | 6 | 3 |
EG: experimental group; CG: control group; PCI: percutaneous coronary intervention; NR: not reported; ACEI: angiotensin-converting enzyme inhibitor; ①: LVEF: left ventricular ejection fraction; ②: LVEDD: left ventricular end-diastolic diameter; ③: NT-proBNP: N-terminal pro-B, type natriuretic peptide; ④: 6-min walk test; ⑤: major adverse cardiovascular event; ⑥: adverse reaction.